Asthma is a chronic respiratory disease characterized by constriction of smooth muscles of lung. Deposition of inhaled drug in respiratory system is the key parameter to treat these obstructive air diseases. Aerodynamic particle size of all inhaled products directly influencing regional deposition of APIs in the lungs and respiratory tract. Its measurement is critical during the product development cycle and for quality control. Cascade impactors are preferable for inhaler characterization because they provide the required degree of resolution in the particle size range of greatest interest between 0.5-5µm for the inhalation products. The aim of this study is to develop the successful method for estimation of triple combination metered dose inhaler Formoterol, Tiotropium and Ciclesonide by HPLC as well as analyze the deposition of the fine particle fraction of active pharmaceutical ingredients of inhaler drug into the in-vitro respiratory tract model (Andersen cascade impactor) with the help of HPLC. Improved APSD of inhalers will help to reduce the dosage and frequency of dosing to patient. HPLC method was developed and validated for measuring particle size deposition of MDI.
Impact Factor
2022: 6.012
This work is licensed under a